Log in
NASDAQ:PODD

Insulet Stock Forecast, Price & News

$225.02
+1.30 (+0.58 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$223.19
Now: $225.02
$233.00
50-Day Range
$198.84
MA: $210.42
$225.59
52-Week Range
$121.00
Now: $225.02
$233.99
Volume1.46 million shs
Average Volume563,851 shs
Market Capitalization$14.77 billion
P/E Ratio803.67
Dividend YieldN/A
Beta0.82
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. It sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, Israel, and internationally. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
Read More
Insulet logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$738.20 million
Cash Flow$0.68 per share
Book Value$1.23 per share

Profitability

Net Income$11.60 million

Miscellaneous

Employees1,350
Market Cap$14.77 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$225.02
+1.30 (+0.58 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Insulet (NASDAQ:PODD) Frequently Asked Questions

How has Insulet's stock price been impacted by COVID-19?

Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PODD stock has increased by 30.7% and is now trading at $225.02.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Insulet?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 11 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Insulet
.

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Insulet
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings results on Thursday, August, 6th. The medical instruments supplier reported $0.22 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.01) by $0.23. The medical instruments supplier earned $226.30 million during the quarter, compared to analysts' expectations of $212.41 million. Insulet had a net margin of 2.20% and a return on equity of 10.96%. The firm's revenue for the quarter was up 27.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.02 EPS.
View Insulet's earnings history
.

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its FY 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $863.694-878.458 million, compared to the consensus revenue estimate of $849.76 million.

What price target have analysts set for PODD?

20 brokers have issued 1-year target prices for Insulet's stock. Their forecasts range from $165.00 to $260.00. On average, they anticipate Insulet's stock price to reach $223.00 in the next year. This suggests that the stock has a possible downside of 0.9%.
View analysts' price targets for Insulet
.

Are investors shorting Insulet?

Insulet saw a increase in short interest in the month of August. As of August 14th, there was short interest totaling 2,840,000 shares, an increase of 10.1% from the July 30th total of 2,580,000 shares. Based on an average trading volume of 494,300 shares, the days-to-cover ratio is presently 5.7 days.
View Insulet's Short Interest
.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Walt Disney (DIS), Square (SQ), salesforce.com (CRM), Roku (ROKU), Trade Desk (TTD) and Tesla (TSLA).

Who are Insulet's key executives?

Insulet's management team includes the following people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 59)
  • Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 47)
  • Mr. Patrick J. Sullivan, Consultant (Age 67)
  • Mr. Michael L. Levitz, Advisor (Age 45)

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by many different institutional and retail investors. Top institutional shareholders include Mint Tower Capital Management B.V. (12.74%), Vanguard Group Inc. (9.07%), Coatue Management LLC (2.22%), William Blair Investment Management LLC (1.43%), Frontier Capital Management Co. LLC (1.29%) and Marshall Wace North America L.P. (1.12%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, Eric Benjamin, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet
.

Which major investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Perceptive Advisors LLC, Victory Capital Management Inc., Marshall Wace North America L.P., Russell Investments Group Ltd., Federated Hermes Inc., Chartwell Investment Partners LLC, and First Trust Advisors LP. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, and Shacey Petrovic.
View insider buying and selling activity for Insulet
.

Which major investors are buying Insulet stock?

PODD stock was bought by a variety of institutional investors in the last quarter, including Mint Tower Capital Management B.V., Holocene Advisors LP, Vanguard Group Inc., Goldman Sachs Group Inc., Alyeska Investment Group L.P., Bellevue Group AG, SeaTown Holdings Pte. Ltd., and Tobam.
View insider buying and selling activity for Insulet
.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $225.02.

How big of a company is Insulet?

Insulet has a market capitalization of $14.77 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

What is Insulet's official website?

The official website for Insulet is www.insulet.com.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.